Print  |  Close

A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Active: No
Cancer Type: Prostate Cancer NCT ID: NCT01995058
Trial Phases: Phase II Protocol IDs: XL184-210 (primary)
Eligibility: 18 and older, Male Study Type: Treatment
Study Sponsor: Exelixis
NCI Full Details:

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.